©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
5`-AMP Activates the AMP-activated Protein Kinase Cascade, and Ca/Calmodulin Activates the Calmodulin-dependent Protein Kinase I Cascade, via Three Independent Mechanisms (*)

(Received for publication, June 22, 1995; and in revised form, September 4, 1995)

Simon A. Hawley (1)(§) Michele A. Selbert (2)(¶) Elaine G. Goldstein (2) Arthur M. Edelman (2)(**) David Carling (3) D. Grahame Hardie (1)

From the  (1)Department of Biochemistry, The University, Dundee, DD1 4HN, Scotland, United Kingdom, the (2)Department of Pharmacology and Toxicology, State University of New York at Buffalo, Buffalo, New York 14214, and the (3)Medical Research Council Molecular Medicine Group, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London, W12 0NN, United Kingdom

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

AMP-activated protein kinase (AMPK) and Ca/calmodulin (CaM)-dependent protein kinase I (CaMKI) are protein kinases that are regulated both by allosteric activation (AMP and Ca/CaM, respectively) and by phosphorylation by upstream protein kinases (AMPK kinase (AMPKK) and CaMKI kinase (CaMKIK), respectively). We now report that AMPKK can activate CaMKI and that, conversely, CaMKIK can activate AMPK. CaMKIK is 68-fold more effective at activating CaMKI than AMPK, while AMPKK is 17-fold more effective at activating AMPK than CaMKI. Our results suggest that CaMKIK and AMPKK are distinct enzymes dedicated to their respective kinase targets but with some overlap in their substrate specificities. The availability of alternative substrates for AMPKK and CaMKIK allowed the unequivocal demonstration that AMP and Ca/calmodulin promote the activation of AMPK and CaMKI, respectively, via three independent mechanisms: 1) direct activation of AMPK and CaMKI, 2) activation of AMPKK and CaMKIK, and 3) by binding to AMPK and CaMKI, inducing exposure of their phosphorylation sites. Since AMP and Ca/calmodulin each has a triple effect in its respective system, in vivo, the two systems would be expected to be exquisitely sensitive to changes in concentration of their respective activating ligands.


INTRODUCTION

The AMP-activated protein kinase (AMPK), (^1)is believed to be involved in protecting cells against ATP depletion due to environmental stress by inactivating several key biosynthetic enzymes(1, 2) . 5`-AMP allosterically activates AMPK (up to 5-fold)(3, 4) , but also promotes the phosphorylation and activation (up to 50-fold) of AMPK by an upstream protein kinase, AMP-activated protein kinase kinase (AMPKK) (5, 6) . Since the two effects multiply, this mechanism ensures a sensitive activation of the system when AMP rises. This happens when ATP is depleted due to displacement of the adenylate kinase reaction (7) . We have proposed that the effect of AMP on AMPK phosphorylation is, at least in part, substrate-mediated, i.e. that binding of the nucleotide to AMPK makes it a better substrate for AMPKK. The evidence was that AMP analogues, which either mimic or antagonize the allosteric effect of AMP on AMPK activity, have the same effects on the phosphorylation of AMPK(6) . However, as no alternative substrates for AMPKK were available, it was difficult to exclude the possibility that AMPKK was directly stimulated by AMP.

Calmodulin-dependent protein kinase-I (CaMKI) is one of a family of Ca/calmodulin-dependent protein kinases (CaM kinases), which also includes CaM kinases II and IV, elongation factor-2 kinase, myosin light chain kinases, and phosphorylase kinase (for review, see (8) and (9) ). Two isoforms of CaMKI, CaMKIa and CaMKIb, have been separately purified from rat brain and characterized(10, 11) . They are similar to purified bovine brain CaMKI (12) and expressed rat and human CaMKI (13, 14) in size, subunit structure, and substrate specificity. CaMKIa was isolated from rat brain in a relatively inactive, apparently nonphosphorylated state, but its activity was enhanced >10-fold by a protein activator. By contrast, CaMKIb was isolated from rat brain in an active, phosphorylated state but could be inactivated by treatment with purified protein phosphatase-2A(10, 11) . The a and b forms of CaMKI may therefore represent dephospho- and phospho- forms respectively, of the same gene product. The activator of CaMKIa has been purified and characterized from pig brain(15) . It is a protein kinase that phosphorylates and activates (up to 50-fold) purified rat brain CaMKIa or expressed human CaMKI(14, 15, 16) . We will refer here to purified rat brain CaMKIa as CaMKI, and CaMKIa activator as CaMKI kinase (CaMKIK). Intriguingly, the phosphorylation and activation of CaMKI by CaMKIK requires Ca/calmodulin(10, 14, 15) . For reasons analogous to those described above for AMPK, it has been difficult to determine whether the effect of Ca/calmodulin is on CaMKI itself or on CaMKIK, especially since both bind to calmodulin-Sepharose in a Ca-dependent manner(11, 15) .

CaMKI and AMPK therefore display one striking similarity in that the activating ligand (Ca/calmodulin or AMP respectively) has a dual effect, causing both direct activation of the downstream protein kinase, and promotion of its phosphorylation and activation by the upstream kinase kinase. A further similarity lies in their substrate specificities, since both CaMKI and AMPK recognize the consensus XRXX(S/T)XXX, where is a hydrophobic residue(17, 18, 19) . Furthermore, although AMPK is not regulated by Ca/calmodulin, the sequence of its kinase domain (and that of its yeast homologue, Snf1p) is closely related to those of members of the calmodulin-dependent protein kinase subfamily(20, 21) . These observations raised the possibility that AMPKK and CaMKIK could be similar or even identical, enzymes. We report here that CaMKIK and AMPKK are distinct, with each preferring its respective kinase target. However their abilities to phosphorylate and activate the heterologous kinases allowed us to dissect the mechanisms of action of the activating ligands, AMP and Ca/calmodulin, in these two protein kinase cascades.


EXPERIMENTAL PROCEDURES

Materials

ATP and calmodulin were from Boehringer Mannheim; [-P]ATP and Hyperfilm MP were from Amersham International, Bucks, UK; okadaic acid was from Life Technologies, Paisley, UK; AMP and agarose-bound 5`-nucleotidase from Crotalusadamanteus were from Sigma, Dorset, UK. All other chemical reagents were of analytic grade from BDH, Poole, Dorset, UK. The catalytic subunit of protein phosphatase-2A (PP2A) was purified from bovine heart as described previously for rabbit muscle (22) . AMPK was purified from rat liver as far as the gel filtration step(4) , except that protein phosphatase inhibitors were excluded from the final step. AMPKK was purified from rat liver as a by-product of the AMPK preparation. (^2)Briefly, protein precipitating between 6 and 10% polyethylene glycol was further purified by chromatography on DEAE-Sepharose, blue-Sepharose, and Q-Sepharose, and active fractions were concentrated using a Centricon-30 (Amicon). CaMKI (Ia form) was purified from rat brain (11) , and CaMKIK was purified from pig brain(15) . AMPK antiserum was raised in rabbits against the peptide PGLKPHPERMPPLI (residues 361-374 of the catalytic subunit)(20) .

Kinase Assays

AMPK and CaMKI were assayed using the peptide AMARAASAAALARRR (19) by a procedure described previously(23) . One unit of AMPK or CaMKI was that amount that catalyzed the incorporation of 1 nmol of phosphate into the peptide/min at 30 °C. AMPKK was assayed by its ability to activate dephosphorylated AMPK. AMPK (2000 units/ml in buffer A (50 mM Na-Hepes, pH 7.0, 1 mM dithiothreitol, 0.02% (w/v) Brij-35)) was inactivated by 80% by treatment at 30 °C with PP2A (10 mU/ml final). PP2A was then inhibited by the addition of okadaic acid to a final concentration of 100 nM. Three volumes of dephosphorylated AMPK were added to 1 volume of buffer A containing ATP, MgCl(2), and AMP to give final concentrations in the AMPKK assay of 200 µM, 5 mM, and 100 µM, respectively. Three volumes of this mixture were then added to 1 volume of AMPKK in buffer A, incubated for 25 min at 30 °C, and 5-µl aliquots were assayed in 25 µl of AMPK assays as described above. One unit of AMPKK is defined as that amount that increases the activity of the dephosphorylated AMPK by 1 unit/ml (calculated at the dilution of the original stock AMPK) in 1 min.

Activation of AMPK/CaMKI

AMPK (dephosphorylated as described above) or CaMKI (purified in the dephosphorylated state), were activated by incubation with either AMPKK or CaMKIK in the presence of MgATP (200 µM) and either 1 mM CaCl(2), 1 µM calmodulin or 100 µM AMP as indicated. Agarose-bound snake venom 5`-nucleotidase (62 milliunits/ml) was included in all incubations that did not contain AMP to remove endogenous AMP. Preparations of AMPK and AMPKK were also pretreated with 5`-nucleotidase-agarose (62 milliunits/ml) for 10 min at 30 °C, the nucleotidase-agarose being removed by centrifugation (14,000 times g for 2 min) prior to the experiment.

Analysis of P-Labeling of AMPK/CaMKI

SDS-PAGE was performed in 10% gels(24) . Radioactivity on dried gels was detected by autoradiography using Hyperfilm MP in Kodak intensifying cassettes or, for quantification of P incorporation, by imaging using a Molecular Dynamics PhosphorImager.


RESULTS

Activation of CaMKI by AMPKK

Fig. 1shows that AMPKK activated CaMKI in the presence of MgATP. In the absence of AMPKK, the activity of CaMKI was undetectable and did not increase on incubation with MgATP either in the presence (not shown) or absence (open circles) of AMP and/or Ca/calmodulin. In the presence of AMPKK, no activation was obtained if the preincubation was performed in the absence of Ca/calmodulin and AMP, other than a small increase that was not dependent on time of preincubation and was therefore due to activation during the subsequent CaMKI assay (which contains Ca/calmodulin). A slow, time-dependent activation was observed in the presence of AMPKK and AMP and a faster activation in the presence of AMPKK plus Ca/calmodulin. The most rapid activation was obtained when AMPKK, AMP, and Ca/calmodulin were all added to the preincubation.


Figure 1: Activation of CaMKI by AMPKK. CaMKI (0.33 µg/ml) was incubated with MgATP as described under ``Experimental Procedures'' in the presence (filled symbols) or absence (open symbols) of AMPKK (8000 units/ml). Incubations also contained no further additions (circles), AMP (triangles), CaCl(2) and calmodulin (Ca/CaM) (squares), or AMP, CaCl(2) and calmodulin (inverted triangles) all at concentrations stated under ``Experimental Procedures.'' Where CaCl(2) and calmodulin were not added, EGTA was added to a final concentration of 2 mM. The small time-independent increase in activity in the presence of AMPKK (compare open and filled circles) is due to activation occurring during the subsequent CaMKI assay, which contains Ca/calmodulin. AMP and/or Ca/calmodulin had no effect in the absence of AMPKK (not shown).



To reproducibly observe the effects of AMP, we included purified 5`-nucleotidase in the minus AMP controls. We previously showed that inclusion of 5`-nucleotidase in minus AMP controls is necessary to observe complete AMP-dependence of the reactivation of AMPK by AMPKK. (^3)The 5`-nucleotidase removes traces of AMP that might have been present in the protein preparations or AMP formed due to trace contamination of one of the preparations with adenylate kinase. The latter enzyme would produce AMP from ADP generated in the kinase reaction. The purified 5`-nucleotidase utilized does not hydrolyze ATP. (^4)

Activation of AMPK by CaMKIK

Fig. 2shows that CaMKIK reactivated AMPK, which had been inactivated by treatment with PP2A. At the point shown by the arrow, okadaic acid was added to inhibit the phosphatase plus MgATP with or without further additions. No activation was obtained in the absence of CaMKIK, either in the presence (not shown) or absence (open circles) of AMP and/or Ca/calmodulin. A very slight activation was observed if the reaction was carried out in the presence of CaMKIK plus Ca/calmodulin. A faster, and more significant, reactivation was obtained in the presence of CaMKIK plus AMP, and this was stimulated an additional 2-fold by the presence of Ca/calmodulin.


Figure 2: Reactivation of dephosphorylated AMPK by CaMKIK. AMPK (6 units/ml) was dephosphorylated using the catalytic subunit of PP2A as described under ``Experimental Procedures.'' At the point shown by the arrow, okadaic acid was added to inhibit PP2A, with MgATP either with (filled symbols) or without (open symbols) CaMKIK (0.07 µg/ml). Where indicated, AMP and/or Ca/calmodulin were also added (concentrations and symbols as for Fig. 1). AMP and/or Ca/calmodulin had no effect in the absence of CaMKIK (not shown).



We also measured the rate of CaMKIK-catalyzed AMPK reactivation as a function of calmodulin concentration in the presence of 200 µM AMP and 1 mM CaCl(2). To measure initial rates, a lower concentration of CaMKIK was used than in Fig. 2. Under these conditions, the rate of activation of AMPK was stimulated 5.6 ± 1.8-fold by Ca/calmodulin with a K(a) of 15 ± 4 nM (Fig. 3).


Figure 3: Effect of calmodulin concentration on the reactivation of AMPK by CaMKIK. Reactivation of AMPK (3 units/ml) was carried out, after dephosphorylation using the catalytic subunit of PP2A, as described under ``Experimental Procedures,'' for 20 min with 0.033 µg/ml CaMKIK in the presence of AMP (100 µM) and CaCl(2) (1 mM) at the indicated calmodulin concentrations.



Effects of AMP and Ca/Calmodulin in Homologous Systems

Fig. 1and Fig. 2show that both the activation of CaMKI by AMPKK and the activation of AMPK by CaMKIK were stimulated by both AMP and Ca/calmodulin. However, when CaMKI was activated in a homologous system using CaMKIK (Fig. 4), activation was observed only in the presence of Ca/calmodulin as reported previously(10, 15) , and AMP had no effect in either the absence or presence of Ca/calmodulin. Similarly, when AMPKK was reactivated using AMPKK, the reaction was almost completely dependent on AMP as reported previously(6, 26) . Ca/calmodulin did not stimulate, and in fact, slightly inhibited, the reaction (Fig. 5).


Figure 4: Activation of CaMKI by CaMKIK. CaMKI (0.33 µg/ml) was incubated with MgATP as described under ``Experimental Procedures,'' in the presence (filled symbols) and absence (open symbols) of CaMKIK (0.055 µg/ml). In some incubations, AMP and/or Ca/calmodulin were also added (concentrations and symbols as for Fig. 1). The time-independent increase of activity in the presence of CaMKIK (compare open and filled circles) is due to activation occurring during the subsequent CaMKI assay, which contains Ca/calmodulin. AMP and/or Ca/calmodulin had no effect in the absence of CaMKIK (not shown).




Figure 5: Reactivation of AMPK by AMPKK. AMPK (6 units/ml) was dephosphorylated using the catalytic subunit of PP2A as described under ``Experimental Procedures.'' At the point shown by the arrow, okadaic acid was added to inhibit PP2A, together with MgATP either with (filled symbols) or without (open symbols) AMPKK (1600 units/ml). In some incubations, AMP and/or Ca/calmodulin were also added (concentrations and symbols as for Fig. 1). AMP and/or Ca/calmodulin had no effect in the absence of AMPKK (not shown).



Phosphorylation of CaMKI by CaMKIK and AMPKK

CaMKI was incubated with [-P]ATP with or without CaMKIK or AMPKK in the presence or absence of AMP and/or Ca/calmodulin and analyzed by SDS-PAGE and autoradiography. For comparison with the phosphorylation of CaMKI, its activation under these conditions was also determined. As reported previously(14, 15) , CaMKIK phosphorylated CaMKI (Ia form, 43 kDa) (Fig. 6, lanes 1 and 2) and a minor component probably representing CaMKIb (39 kDa). P-Labeling of these polypeptides was not evident when CaMKI (lane 7) or CaMKIK (lane 8) was incubated alone. Phosphorylation of CaMKI by CaMKIK was not stimulated by AMP (compare lanes 1 and 2), indicating that AMP neither activates CaMKIK nor binds to CaMKI to promote exposure of a phosphorylation site. Incubation with AMPKK also resulted in P-labeling of CaMKI (lanes 3-6). In this case, labeling was stimulated by AMP (compare lane 5 with lane 3 or lane 6 with lane 4). There also appeared to be some stimulation by Ca/calmodulin, (for example, compare lane 6 with lane 5), so that that the greatest enhancement of AMPKK-catalyzed phosphorylation of CaMKI was observed in the presence of both AMP and Ca/calmodulin. From the results of Fig. 1and Fig. 6, it may be concluded that maximal phosphorylation and activation of CaMKI by AMPKK requires both AMP and Ca/calmodulin.


Figure 6: Phosphorylation of CaMKI by CaMKIK and AMPKK. CaMKI (0.8 µg/ml) was incubated with [-P]ATP for 40 min at 30 °C, with or without CaMKIK (0.055 µg/ml), AMPKK (4000 units/ml), and AMP and/or CaCl(2) and calmodulin (concentrations as given under ``Experimental Procedures''), as indicated. The reaction was stopped by adding SDS sample buffer, and the mixture was analyzed by SDS-PAGE and autoradiography. The area containing CaMKI (Ia form, 43 kDa) is shown with its migration indicated by the arrow. The less prominently labeled band below CaMKIa probably represents a minor amount of the Ib form of CaMKI (39 kDa). Values at the bottom show the activation of CaMKI obtained under each condition, expressed as a percentage of the maximal activation obtained with CaMKIK.



Phosphorylation of AMPK by AMPKK and CaMKIK

AMPK was incubated with [-P]ATP with or without AMPKK or CaMKIK in the presence or absence of AMP and/or Ca/calmodulin, immunoprecipitated using antiserum against a peptide sequence in its 63-kDa catalytic subunit (p63), and analyzed by SDS-PAGE and phosphorimaging and autoradiography (Fig. 7). To observe effects of the activating ligands on phosphorylation, the incubation time and concentrations of AMPK or CaMKIK were chosen such that the greatest activation observed under any condition was 33% of maximal activation obtained with AMPKK. When AMPK was incubated alone with [-P]ATP in the presence of Ca/calmodulin, there was no significant autophosphorylation of p63 (lane 8). There was a low level of autophosphorylation when AMP was also added (lane 7), but this was not accompanied by activation of the kinase, indicating that the phosphorylation occurred at nonactivating sites. When AMPK was incubated with AMP, Ca/calmodulin, and sufficient AMPKK to give 16% activation, the phosphorylation of p63 (lane 1) was significantly higher (1.4-fold) than the relevant autophosphorylation control (lane 7). Both activation and phosphorylation of p63 were higher in the absence of Ca/calmodulin (compare lane 2 with lane 1), consistent with the observation in Fig. 5that Ca/calmodulin inhibits activation of AMPK by AMPKK. When AMPK was incubated with CaMKIK in the absence of activating ligand, little phosphorylation of p63 or activation of AMPK was observed (lane 3). When Ca/calmodulin was also added, both phosphorylation of p63 and activation (4% maximal) were slightly stimulated (lane 4). AMP on its own caused a slightly greater degree of activation of AMPK by CaMKIK (7% maximal), correlating with markedly higher phosphorylation of p63 (lane 5). The greatest effects of CaMKIK both on activation of AMPK (33% maximal) and p63 phosphorylation (lane 6, 1.9-fold above autophosphorylation control, lane 7) were obtained in the presence of both AMP and Ca/calmodulin. From the results of Fig. 2and 7, it may be concluded that maximal phosphorylation and activation of AMPK by CaMKIK requires both AMP and Ca/calmodulin.


Figure 7: Phosphorylation of p63, the catalytic subunit of AMPK, by AMPKK and CaMKIK. AMPK (55 units/ml) was incubated with [-P]ATP for 15 min at 30 °C with or without AMPKK (1600 units/ml), CaMKIK (0.05 µg/ml), and AMP and/or CaCl(2) and calmodulin (concentrations given under ``Experimental Procedures''), as indicated. The reaction was stopped by adding EDTA to a final concentration of 5 mM, and AMPK was immunoprecipitated. The photograph shows an autoradiogram of the SDS-PAGE gel of the immunoprecipitate. Values for p63 phosphorylation represent radioactivity in the p63 band estimated using phosphorimaging. The migration of p63 is indicated by the arrow. Values at the bottom show the activation of AMPK obtained under each condition, expressed as a percentage of the maximal activation obtained with AMPKK.



Collectively, the results of Fig. 1Fig. 2Fig. 3Fig. 4Fig. 5Fig. 6Fig. 7are consistent with a model in which AMP and Ca/calmodulin, promote the phosphorylation and activation of AMPK and CaMKI by both substrate- and enzyme-directed effects. In the activation of CaMKI by AMPKK, Ca/calmodulin binds to the former (exposing a phosphorylation site), and AMP binds to the latter (directly enhancing its activity). In the activation of AMPK by CaMKIK, AMP binds to the former (exposing a phosphorylation site) and Ca/calmodulin binds to the latter (directly enhancing its activity). In the homologous reactions, a single allosteric activator (either Ca/calmodulin or AMP depending on the system) is sufficient for both substrate- and enzyme-directed effects.

AMPKK and CaMKIK Are Distinct Enzymes

The use of the heterologous reactions to probe the activation mechanisms is based on AMPKK and CaMKIK being distinct enzymes but with some cross-reactivity toward the kinase targets. We also considered two alternative explanations, the first that CaMKIK and AMPKK are identical, i.e. that a common protein kinase regulates both CaMKI and AMPK, and the second that the preparations of CaMKIK and AMPKK might be cross-contaminated.

The first alternative explanation is ruled out by the following observations. 1) CaMKIK and AMPKK are highly selective toward their respective kinase targets. This was quantified by determining the preference of each kinase kinase for the two kinase substrates. We expressed the activity of the two preparations as the percentage of maximal activation (i.e. of that achieved with maximal amounts of the homologous kinase kinase)/min/µl of preparation. The kinase kinase preparations were diluted such that a linear increase in activity was obtained with time. For CaMKIK, the activity was 24.4% of maximum/min/µl using CaMKI as substrate and 0.36% of maximum/min/µl with AMPK as substrate. For AMPKK, the activity was 13.4% of maximum/min/µl with AMPK as substrate and 0.78% of maximum/min/µl with CaMKI as substrate. CaMKIK was therefore 68-fold more active toward CaMKI than AMPK, whereas AMPKK was 17-fold more active toward AMPK than CaMKI. 2) CaMKIK (15) but not AMPKK (data not shown) bound to calmodulin-Sepharose in a Ca-dependent manner. 3) The allosteric activators of AMPKK and CaMKIK are different. This is most clearly seen when the two kinase kinases are compared using a single kinase target and an allosteric activator that does not bind to the kinase target itself. Activation of CaMKI by AMPKK (Fig. 1), but not by CaMKIK (Fig. 4), was stimulated by AMP. And, activation of AMPK by CaMKIK (Fig. 2), but not by AMPKK (Fig. 5), was stimulated by Ca/calmodulin. Thus, AMPKK is stimulated by AMP but not Ca/calmodulin, while CaMKIK is stimulated by Ca/calmodulin, but not AMP.

The second alternative explanation, that the preparations of AMPKK and CaMKIK were cross-contaminated, is ruled out for the following reasons. 1) CaMKIK was purified by Cadependent affinity chromatography on calmodulin-Sepharose(15) , to which AMPKK does not bind. 2) During the purification of AMPKK, CaMKI-activating activity exactly comigrated with AMPK-activating activity on the last two column steps, Q-Sepharose, and Mg gradient elution from Mono-Q, making it very unlikely that the minor CaMKI-activating activity detected was due to residual unresolved CaMKIK but indicating rather that this activity was an intrinsic property of AMPKK itself. 3) The acceleration in the rate of CaMKI activation by AMP in the presence of AMPKK (Fig. 1) but not CaMKIK (Fig. 4) can only be explained by an authentic capacity of AMPKK to phosphorylate and activate CaMKI. Similarly, the accelerated activation of AMPK by Ca/calmodulin in the presence of CaMKIK (Fig. 2) but not AMPKK (Fig. 5) can only be explained by an authentic capacity of CaMKIK to phosphorylate and activate AMPK.


DISCUSSION

As shown by these results, AMPKK and CaMKIK are kinase kinases each with some capacity to phosphorylate and activate the respective heterologous kinase target. Given that the heterologous reactions are catalyzed at a small fraction of the rate of the homologous reactions, these cross-reactivities may not be physiologically significant, although this is difficult to exclude at present. The cross-reactivities are explainable by assuming that AMPKK and CaMKIK are representatives of a related family of kinase kinases, which recognizes similar phosphorylation site sequences. In the case of CaMKI, this site has been recently identified as Thr-177 located in the ``activation loop'' of the catalytic domain(14) . Efforts are currently underway to identify the activating phosphorylation site in AMPK.

The studies described here have also identified for the first time an alternative substrate for AMPKK, and for CaMKIK, the first instance of an alternative substrate regulated by a distinct activating ligand, since although CaMKIK does phosphorylate and activate CaMKIV(27) , the latter is also Ca/calmodulin-regulated. The availability of alternative substrates regulated by distinct activating ligands has allowed us, by analysis of the heterologous systems, to demonstrate that in these two protein kinase cascades, the regulatory molecules (Ca/calmodulin and AMP) both have three independent effects (schematically illustrated in Fig. 8).


Figure 8: Triple effects of AMP and Ca/calmodulin (Ca/CaM) on the AMPK and CaMKI protein kinase cascades. The heavy arrows indicate that the activating ligands have three effects: 1) direct allosteric activation of the downstream protein kinase; 2) binding to the downstream protein kinase and making it a better substrate for the upstream protein kinase; 3) direct activation of the upstream protein kinase. Existing evidence suggests that activation of AMPK is reversed by protein phosphatase 2C (PP2C)(25, 26) . PP? indicates that the protein phosphatase responsible for dephosphorylation of CaMKI is not known, although CaMKI can be deactivated in vitro by the catalytic subunit of PP2A (10) .



The first role described for Ca/calmodulin in the regulation of CaMKI activity was that of a direct activator (10, 11, 12) . The mechanism of this activation involves relief of intrasteric autoinhibition via identified calmodulin-binding and autoinhibitory domains(14) . In addition to this classic role, Ca/calmodulin is also required for the phosphorylation and activation of CaMKI by CaMKIK (Refs. 10, 14, and 15; see also Fig. 4). We show here that this latter role itself occurs through two distinct effects. Since phosphorylation and activation of AMPK by CaMKIK was stimulated by Ca/calmodulin ( Fig. 2and Fig. 7), CaMKIK is itself a Ca/calmodulin-stimulated enzyme. And since phosphorylation and activation of CaMKI by AMPKK was stimulated by Ca/calmodulin ( Fig. 1and Fig. 6), the latter is also exerting an effect at the level of the substrate (CaMKI), to expose the site of phosphorylation. These results are supported by experiments with expressed native and mutated forms of human CaMKI in that mimicking calmodulin-binding by C-terminal truncation of the calmodulin-binding/autoinhibitory domain of CaMKI promoted its phosphorylation by CaMKIK, and phosphorylation of the calmodulin-independent CaMKI mutant by CaMKIK was still accelerated by Ca/calmodulin(14) .

Similarly, AMP both directly activates AMPK and promotes its phosphorylation by AMPKK ( (5) and (6) ; see also Fig. 5). We show here that this latter role itself occurs through two distinct effects. Since phosphorylation and activation of CaMKI by AMPKK was stimulated by AMP ( Fig. 1and Fig. 6), AMPKK is itself an AMP-activated protein kinase. AMP also stimulated the phosphorylation of several polypeptides in the AMPKK preparation (data not shown), further supporting the idea that AMPKK is an AMP-activated protein kinase. And since phosphorylation and activation of AMPK by CaMKIK was also stimulated by AMP (Fig. 2, 7), the latter is also exerting an effect at the level of the substrate (AMPK), to expose the site of phosphorylation.

Since CaMKIK is Ca/calmodulin-activated, we determined the concentration of calmodulin that gave half-maximal CaMKIK activation. The value obtained, 15 ± 4 nM, is within the range found for other calmodulin-activated enzymes(8, 9) . Interestingly, CaMKIK appears to have a significant basal activity in the absence of Ca/calmodulin ( Fig. 2and Fig. 3) and thus differs from most other calmodulin-activated enzymes, which are essentially completely dependent on calmodulin. We also consistently find that 25% of CaMKIK does not bind to calmodulin-Sepharose (data not shown; (15) ). One explanation is that CaMKIK exists in an equilibrium between active and inactive conformations, and calmodulin binds with high affinity only to the latter, converting it to the active conformation. Our results also demonstrate that AMPKK is itself an AMP-activated protein kinase. However, because it was necessary to add 5`-nucleotidase to the minus AMP controls to observe the effects of AMP, it was not possible to determine the concentration dependence of AMPKK on AMP.

These findings that in the AMPK and CaMKI systems both the upstream and downstream protein kinases are regulated by the same activating ligand is not without precedent, since cyclin-dependent kinase-activating kinase, the protein kinase that phosphorylates the activating threonine of cyclin-dependent protein kinases, is itself a cyclin-dependent protein kinase(28, 29, 30) . As in our systems, binding of the activating ligand (cyclin) to the downstream protein kinase stimulates both the activity of the downstream kinase and its phosphorylation by the upstream protein kinase(31) . The cyclin-dependent kinase-activating kinase/cyclin-dependent protein kinase system differs in that the cyclin proteins that activate the upstream and downstream protein kinases are distinct(32, 33, 34) . We are not aware of a precedent where the identical activating ligand (AMP or Ca/calmodulin) has three effects on a protein kinase cascade. We propose that the triple actions of AMP and Ca/calmodulin on their respective systems would make these systems respond in an exquisitely sensitive manner to small changes in the concentrations of the activating ligand. Although the allosteric regulators differ between the two systems, our study demonstrates a remarkable analogy between CaMKI and AMPK. We have already shown another striking similarity, in that the substrate sequence motifs recognized by these two protein kinases are very similar(17, 18, 19) . These similarities in specificity, and in recognition by the upstream protein kinases presumably reflect the fact that the kinase domains of rat CaMKI and rat AMPK (13, 20) are 40% identical in sequence and phylogenetic analysis of kinase domain sequences places both within the same protein kinase subfamily(21) . On the other hand, the two kinases are unrelated outside of the kinase domain, which is presumably where the binding sites for the distinct activating ligands are located.

Okuno et al.(35) and Tokumitsu et al.(36, 37) have recently reported that calmodulin-dependent protein kinase IV (CaMKIV) is also regulated in a Ca/calmodulin-dependent manner by an activator protein kinase (CaMKIV kinase). In this case, it is not clear whether the effect of Ca/calmodulin to promote CaMKIV phosphorylation is due to binding to CaMKIV kinase, to CaMKIV, or both, although it is intriguing that CaMKIV kinase, like CaMKIK, binds to calmodulin-Sepharose(36, 37) . Moreover, CaMKIK also activates CaMKIV and does so by phosphorylating the equivalent threonine residue (Thr-196) to that phosphorylated in CaMKI (Thr-177) (14, 27) . The precise relationship between CaMKIV kinase and CaMKIK remains to be established.

It is also interesting to compare AMPK and CaMKI with calmodulin-dependent protein kinase II (CaMKII), which is regulated by autophosphorylation on Thr-286. Autophosphorylation of the latter is an intersubunit reaction occurring between neighboring subunits of the multimeric enzyme. Ca/calmodulin appears to play a role in CaMKII phosphorylation analogous to its role in CaMKI (and AMPK) phosphorylation in that it is required not only to initially activate the CaMKII subunit, which is acting as the kinase, but also must be bound to the neighboring subunit in order for it to act as a substrate (38) . An important difference between CaMKI and CaMKII is that phosphorylation occurs at nonequivalent sites(14) . Another major difference is that autophosphorylation of CaMKII on Thr-286 converts it from an active and Ca/calmodulin-dependent form to a Ca/calmodulin-independent form, whereas phosphorylation of CaMKI by CaMKIK converts it from an inactive form to an active and Ca/calmodulindependent form(10, 15) . CaMKIV incorporates both forms of regulation, since its phosphorylation by CaMKIK or CaMKIV kinase activates and imparts partial Ca/calmodulinindependence(27, 35, 36) .

In conclusion, studies described here indicate that the apparent relatedness of the calmodulin-dependent protein kinase kinases described to date extends beyond the immediate calmodulin-dependent protein kinase subfamily to that regulated by a distinct allosteric activator (AMP). This relationship is seen both in the ability of AMPKK and CaMKIK to cross-regulate the heterologous downstream kinases, as well as in the remarkable similarity of the roles of the allosteric activators (AMP and Ca/calmodulin) in the activation process. Despite our findings that the upstream protein kinases have a limited ability to activate the alternative downstream protein kinases in vitro, we suspect that they are likely to be dedicated to their respective downstream protein kinases in vivo, and would thus constitute elements in separate signal transduction cascades akin for example, to the MAP kinase kinase/MAP kinase signaling module. For both the AMP-regulated and Ca/calmodulin-regulated pathways, an important question for future consideration is the quantitative significance of the direct activation of the upstream protein kinases by the respective allosteric activators, relative to the dual effects of the activators on the downstream protein kinases. Studies of analogues that differentially activate or inhibit the upstream and downstream protein kinases or of mutant kinase kinases or kinases that do not respond to the activators will be necessary to address these questions.


FOOTNOTES

*
These studies were supported by a Program Grant from the Wellcome Trust (to D. G. H.) and by National Institutes of Health Grant NS24738 (to A. M. E.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Supported by a Science and Engineering Research Council studentship, sponsored in part by the Medical Research Council Molecular Medicine Unit, Hammersmith Hospital, London.

Supported by National Institutes of Health Training Grant GM07145-20.

**
To whom correspondence should be addressed. Tel.: 716-829-3491; Fax: 716-829-2801.

(^1)
The abbreviations used are: AMPK, AMP-activated protein kinase; AMPKK, AMP-activated protein kinase kinase; CaMKI, Ca/calmodulin-dependent protein kinase I; CaMKIK (CaMKIa activator, CaMKIa kinase), Ca/calmodulin-dependent protein kinase I kinase; PP2A, catalytic subunit of protein phosphatase-2A; PAGE, polyacrylamide gel electrophoresis.

(^2)
S. A. Hawley, personal communication.

(^3)
J. M. Corton, J. G. Gillespie, S. A. Hawley, and D. G. Hardie, submitted for publication.

(^4)
W. Wilson, unpublished results.


REFERENCES

  1. Hardie, D. G., Carling, D., and Halford, N. G. (1994) Semin. Cell Biol. 5, 409-416 [CrossRef][Medline] [Order article via Infotrieve]
  2. Corton, J. M., Gillespie, J. G., and Hardie, D. G. (1994) Curr. Biol. 4, 315-324 [Medline] [Order article via Infotrieve]
  3. Ferrer, A., Caelles, C., Massot, N., and Hegardt, F. G. (1985) Biochem. Biophys. Res. Commun. 132, 497-504 [Medline] [Order article via Infotrieve]
  4. Carling, D., Clarke, P. R., Zammit, V. A., and Hardie, D. G. (1989) Eur. J. Biochem. 186, 129-136 [Abstract]
  5. Moore, S. K., Rijli, F., and Appella, E. (1990) DNA Cell Biol. 9, 387-400 [Medline] [Order article via Infotrieve]
  6. Weekes, J., Hawley, S. A., Corton, J., Shugar, D., and Hardie, D. G. (1994) Eur. J. Biochem. 219, 751-757 [Abstract]
  7. Hardie, D. G., and MacKintosh, R. W. (1992) BioEssays 14, 699-704 [Medline] [Order article via Infotrieve]
  8. Edelman, A. M., Blumenthal, D. K., and Krebs, E. G. (1987) Annu. Rev. Biochem. 56, 567-613 [CrossRef][Medline] [Order article via Infotrieve]
  9. Hanson, P. I., and Schulman, H. (1992) Annu. Rev. Biochem. 61, 559-601 [CrossRef][Medline] [Order article via Infotrieve]
  10. DeRemer, M. F., Saeli, R. J., Brautigan, D. L., and Edelman, A. M. (1992) J. Biol. Chem. 267, 13466-71 [Abstract/Free Full Text]
  11. DeRemer, M. F., Saeli, R. J., and Edelman, A. M. (1992) J. Biol. Chem. 267, 13460-13465 [Abstract/Free Full Text]
  12. Nairn, A. C., and Greengard, P. (1987) J. Biol. Chem. 262, 7273-7281 [Abstract/Free Full Text]
  13. Picciotto, M. R., Czernik, A. J., and Nairn, A. C. (1993) J. Biol. Chem. 268, 26512-26521 [Abstract/Free Full Text]
  14. Haribabu, B., Hook, S. A., Selbert, M. A., Goldstein, E. G., Tomhave, E. D., Edelman, A. M., Snyderman, R., and Means, A. R. (1995) EMBO J. 15, 3679-3686
  15. Lee, J. C., and Edelman, A. M. (1994) J. Biol. Chem. 269, 2158-2164 [Abstract/Free Full Text]
  16. Lee, J. C., and Edelman, A. M. (1995) Biochem. Biophys. Res. Commun. 210, 631-637 [CrossRef][Medline] [Order article via Infotrieve]
  17. Lee, J. C., Kwon, Y. G., Lawrence, D. S., and Edelman, A. M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 6413-6417 [Abstract]
  18. Weekes, J., Ball, K. L., Caudwell, F. B., and Hardie, D. G. (1993) FEBS Lett. 334, 335-339 [CrossRef][Medline] [Order article via Infotrieve]
  19. Dale, S., Wilson, W. A., Edelman, A. M., and Hardie, D. G. (1994) FEBS Lett. 361, 191-195 [CrossRef]
  20. Carling, D., Aguan, K., Woods, A., Verhoeven, A. J. M., Beri, R. K., Brennan, C. H., Sidebottom, C., Davison, M. D., and Scott, J. (1994) J. Biol. Chem. 269, 11442-11448 [Abstract/Free Full Text]
  21. Hanks, S. K., and Hunter, T. (1995) in The Protein Kinase Factsbook (Hardie, D. G., and Hanks, S. K., eds) pp. 7-47, Academic Press, London
  22. Cohen, P., Alemany, S., Hemmings, B. A., Resink, T. J., Strålfors, P., and Lim, T. H. (1988) Methods Enzymol. 159, 390-408 [Medline] [Order article via Infotrieve]
  23. Davies, S. P., Carling, D., and Hardie, D. G. (1989) Eur. J. Biochem. 186, 123-128 [Abstract]
  24. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  25. Clarke, P. R., Moore, F., and Hardie, D. G. (1991) Adv. Protein Phosphatases 6, 187-209
  26. Moore, F., Weekes, J., and Hardie, D. G. (1991) Eur. J. Biochem. 199, 691-697 [Abstract]
  27. Selbert, M. A., Anderson, K. A., Huang, Q.-H., Goldstein, E. G., Means, A. R., and Edelman, A. M. (1995) J. Biol. Chem. 270, 17616-17621 [Abstract/Free Full Text]
  28. Solomon, M. J., Harper, J. W., and Shuttleworth, J. (1993) EMBO J. 12, 3133-3142 [Abstract]
  29. Fesquet, D., Labbe, J. C., Derancourt, J., Capony, J. P., Galas, S., Girard, F., Lorca, T., Shuttleworth, J., Doree, M., and Cavadore, J. C. (1993) EMBO J. 12, 3111-3121 [Abstract]
  30. Poon, R. Y. C., Yamashita, K., Adamczewski, J. P., Hunt, T., and Shuttleworth, J. (1993) EMBO J. 12, 3123-3132 [Abstract]
  31. Desai, D., Wessling, H. C., Fisher, R. P., and Morgan, D. O. (1995) Mol. Cell. Biol. 15, 345-350 [Abstract]
  32. Fisher, R. P., and Morgan, D. O. (1994) Cell 78, 713-724 [Medline] [Order article via Infotrieve]
  33. Makela, T. P., Tassan, J. P., Nigg, E. A., Frutiger, S., Hughes, G. J., and Weinberg, R. A. (1994) Nature 371, 254-257 [CrossRef][Medline] [Order article via Infotrieve]
  34. Labbe, J. C., Martinez, A. M., Fesquet, D., Capony, J. P., Darbon, J. M., Derancourt, J., Devault, A., Morin, N., Cavadore, J. C., and Doree, M. (1994) EMBO J. 13, 5155-5164 [Abstract]
  35. Okuno, S., Kitani, T., and Fujisawa, H. (1994) J. Biochem. (Tokyo) 116, 923-930 [Abstract]
  36. Tokumitsu, H., Brickey, D. A., Glod, J., Hidaka, H., Sikela, J., and Soderling, T. R. (1994) J. Biol. Chem. 269, 28640-28647 [Abstract/Free Full Text]
  37. Tokumitsu, H., Enslen, H., and Soderling, T. R. (1995) J. Biol. Chem. 270, 19320-19324 [Abstract/Free Full Text]
  38. Hanson, P. I., Meyer, T., Stryer, L., and Schulman, H. (1994) Neuron 12, 943-56 [Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.